Danaher acquisition of Abcam would be attractive, says Barclays

290Barclays keeps an Overweight rating on Danaher (DHR) with a $290 price target after Reuters reported the company is the leading contender to acquire Abcam (ABCM), a global life sciences supplier of antibodies and reagents. Abcam would be an attractive bolt-on a acquisition for Danaher, given its solid fundamental profile, the analyst tells investors in a research note. The firm sees “plenty of synergy opportunity that should make a synergized deal multiple a lot more palatable.” Barclays thinks the proposed deal is favorable to Danaher’s overall portfolio and that Abcam fits most aspects of what the company looks for in a new business.